Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases

Anna Villar-Piqué, Matthias Schmitz, Ingolf Lachmann, André Karch, Olga Calero, Christiane Stehmann, Shannon Sarros, Anna Ladogana, Anna Poleggi, Isabel Santana, Isidre Ferrer, Eva Mitrova, Dana Žáková, Maurizio Pocchiari, Inês Baldeiras, Miguel Calero, Steven J. Collins, Michael D. Geschwind, Raquel Sánchez-Valle, Inga Zerr & 1 others Franc Llorens

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Cerebrospinal fluid (CSF) total prion protein (t-PrP) is decreased in sporadic Creutzfeldt-Jakob disease (sCJD). However, data on the comparative signatures of t-PrP across the spectrum of prion diseases, longitudinal changes during disease progression, and levels in pre-clinical cases are scarce. T-PrP was quantified in neurological diseases (ND, n = 147) and in prion diseases from different aetiologies including sporadic (sCJD, n = 193), iatrogenic (iCJD, n = 12) and genetic (n = 209) forms. T-PrP was also measured in serial lumbar punctures obtained from sCJD cases at different symptomatic disease stages, and in asymptomatic prion protein gene (PRNP) mutation carriers. Compared to ND, t-PrP concentrations were significantly decreased in sCJD, iCJD and in genetic prion diseases associated with the three most common mutations E200K, V210I (associated with genetic CJD) and D178N-129M (associated with fatal familial insomnia). In contrast, t-PrP concentrations in P102L mutants (associated with the Gerstmann-Sträussler-Scheinker syndrome) remained unaltered. In serial lumbar punctures obtained at different disease stages of sCJD patients, t-PrP concentrations inversely correlated with disease progression. Decreased mean t-PrP values were detected in asymptomatic D178-129M mutant carriers, but not in E200K and P102L carriers. The presence of low CSF t-PrP is common to all types of prion diseases regardless of their aetiology albeit with mutation-specific exceptions in a minority of genetic cases. In some genetic prion disease, decreased levels are already detected at pre-clinical stages and diminish in parallel with disease progression. Our data indicate that CSF t-PrP concentrations may have a role as a pre-clinical or early symptomatic diagnostic biomarker in prion diseases as well as in the evaluation of therapeutic interventions.

Original languageEnglish
JournalMolecular Neurobiology
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Prion Diseases
Cerebrospinal Fluid
Disease Progression
Inborn Genetic Diseases
Spinal Puncture
Mutation
Fatal Familial Insomnia
Prion Proteins
Biomarkers
Sporadic Creutzfeldt-Jakob Disease

Keywords

  • Cerebrospinal fluid
  • Genetic prion disease
  • Iatrogenic prion disease
  • Prion protein
  • Sporadic Creutzfeldt-Jakob disease

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Neurology
  • Cellular and Molecular Neuroscience

Cite this

Villar-Piqué, A., Schmitz, M., Lachmann, I., Karch, A., Calero, O., Stehmann, C., ... Llorens, F. (Accepted/In press). Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases. Molecular Neurobiology. https://doi.org/10.1007/s12035-018-1251-1

Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases. / Villar-Piqué, Anna; Schmitz, Matthias; Lachmann, Ingolf; Karch, André; Calero, Olga; Stehmann, Christiane; Sarros, Shannon; Ladogana, Anna; Poleggi, Anna; Santana, Isabel; Ferrer, Isidre; Mitrova, Eva; Žáková, Dana; Pocchiari, Maurizio; Baldeiras, Inês; Calero, Miguel; Collins, Steven J.; Geschwind, Michael D.; Sánchez-Valle, Raquel; Zerr, Inga; Llorens, Franc.

In: Molecular Neurobiology, 01.01.2018.

Research output: Contribution to journalArticle

Villar-Piqué, A, Schmitz, M, Lachmann, I, Karch, A, Calero, O, Stehmann, C, Sarros, S, Ladogana, A, Poleggi, A, Santana, I, Ferrer, I, Mitrova, E, Žáková, D, Pocchiari, M, Baldeiras, I, Calero, M, Collins, SJ, Geschwind, MD, Sánchez-Valle, R, Zerr, I & Llorens, F 2018, 'Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases', Molecular Neurobiology. https://doi.org/10.1007/s12035-018-1251-1
Villar-Piqué A, Schmitz M, Lachmann I, Karch A, Calero O, Stehmann C et al. Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases. Molecular Neurobiology. 2018 Jan 1. https://doi.org/10.1007/s12035-018-1251-1
Villar-Piqué, Anna ; Schmitz, Matthias ; Lachmann, Ingolf ; Karch, André ; Calero, Olga ; Stehmann, Christiane ; Sarros, Shannon ; Ladogana, Anna ; Poleggi, Anna ; Santana, Isabel ; Ferrer, Isidre ; Mitrova, Eva ; Žáková, Dana ; Pocchiari, Maurizio ; Baldeiras, Inês ; Calero, Miguel ; Collins, Steven J. ; Geschwind, Michael D. ; Sánchez-Valle, Raquel ; Zerr, Inga ; Llorens, Franc. / Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases. In: Molecular Neurobiology. 2018.
@article{25dedb58d1ae4641917bacc1f8ded389,
title = "Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases",
abstract = "Cerebrospinal fluid (CSF) total prion protein (t-PrP) is decreased in sporadic Creutzfeldt-Jakob disease (sCJD). However, data on the comparative signatures of t-PrP across the spectrum of prion diseases, longitudinal changes during disease progression, and levels in pre-clinical cases are scarce. T-PrP was quantified in neurological diseases (ND, n = 147) and in prion diseases from different aetiologies including sporadic (sCJD, n = 193), iatrogenic (iCJD, n = 12) and genetic (n = 209) forms. T-PrP was also measured in serial lumbar punctures obtained from sCJD cases at different symptomatic disease stages, and in asymptomatic prion protein gene (PRNP) mutation carriers. Compared to ND, t-PrP concentrations were significantly decreased in sCJD, iCJD and in genetic prion diseases associated with the three most common mutations E200K, V210I (associated with genetic CJD) and D178N-129M (associated with fatal familial insomnia). In contrast, t-PrP concentrations in P102L mutants (associated with the Gerstmann-Str{\"a}ussler-Scheinker syndrome) remained unaltered. In serial lumbar punctures obtained at different disease stages of sCJD patients, t-PrP concentrations inversely correlated with disease progression. Decreased mean t-PrP values were detected in asymptomatic D178-129M mutant carriers, but not in E200K and P102L carriers. The presence of low CSF t-PrP is common to all types of prion diseases regardless of their aetiology albeit with mutation-specific exceptions in a minority of genetic cases. In some genetic prion disease, decreased levels are already detected at pre-clinical stages and diminish in parallel with disease progression. Our data indicate that CSF t-PrP concentrations may have a role as a pre-clinical or early symptomatic diagnostic biomarker in prion diseases as well as in the evaluation of therapeutic interventions.",
keywords = "Cerebrospinal fluid, Genetic prion disease, Iatrogenic prion disease, Prion protein, Sporadic Creutzfeldt-Jakob disease",
author = "Anna Villar-Piqu{\'e} and Matthias Schmitz and Ingolf Lachmann and Andr{\'e} Karch and Olga Calero and Christiane Stehmann and Shannon Sarros and Anna Ladogana and Anna Poleggi and Isabel Santana and Isidre Ferrer and Eva Mitrova and Dana Ž{\'a}kov{\'a} and Maurizio Pocchiari and In{\^e}s Baldeiras and Miguel Calero and Collins, {Steven J.} and Geschwind, {Michael D.} and Raquel S{\'a}nchez-Valle and Inga Zerr and Franc Llorens",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s12035-018-1251-1",
language = "English",
journal = "Molecular Neurobiology",
issn = "0893-7648",
publisher = "Humana Press Inc.",

}

TY - JOUR

T1 - Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases

AU - Villar-Piqué, Anna

AU - Schmitz, Matthias

AU - Lachmann, Ingolf

AU - Karch, André

AU - Calero, Olga

AU - Stehmann, Christiane

AU - Sarros, Shannon

AU - Ladogana, Anna

AU - Poleggi, Anna

AU - Santana, Isabel

AU - Ferrer, Isidre

AU - Mitrova, Eva

AU - Žáková, Dana

AU - Pocchiari, Maurizio

AU - Baldeiras, Inês

AU - Calero, Miguel

AU - Collins, Steven J.

AU - Geschwind, Michael D.

AU - Sánchez-Valle, Raquel

AU - Zerr, Inga

AU - Llorens, Franc

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Cerebrospinal fluid (CSF) total prion protein (t-PrP) is decreased in sporadic Creutzfeldt-Jakob disease (sCJD). However, data on the comparative signatures of t-PrP across the spectrum of prion diseases, longitudinal changes during disease progression, and levels in pre-clinical cases are scarce. T-PrP was quantified in neurological diseases (ND, n = 147) and in prion diseases from different aetiologies including sporadic (sCJD, n = 193), iatrogenic (iCJD, n = 12) and genetic (n = 209) forms. T-PrP was also measured in serial lumbar punctures obtained from sCJD cases at different symptomatic disease stages, and in asymptomatic prion protein gene (PRNP) mutation carriers. Compared to ND, t-PrP concentrations were significantly decreased in sCJD, iCJD and in genetic prion diseases associated with the three most common mutations E200K, V210I (associated with genetic CJD) and D178N-129M (associated with fatal familial insomnia). In contrast, t-PrP concentrations in P102L mutants (associated with the Gerstmann-Sträussler-Scheinker syndrome) remained unaltered. In serial lumbar punctures obtained at different disease stages of sCJD patients, t-PrP concentrations inversely correlated with disease progression. Decreased mean t-PrP values were detected in asymptomatic D178-129M mutant carriers, but not in E200K and P102L carriers. The presence of low CSF t-PrP is common to all types of prion diseases regardless of their aetiology albeit with mutation-specific exceptions in a minority of genetic cases. In some genetic prion disease, decreased levels are already detected at pre-clinical stages and diminish in parallel with disease progression. Our data indicate that CSF t-PrP concentrations may have a role as a pre-clinical or early symptomatic diagnostic biomarker in prion diseases as well as in the evaluation of therapeutic interventions.

AB - Cerebrospinal fluid (CSF) total prion protein (t-PrP) is decreased in sporadic Creutzfeldt-Jakob disease (sCJD). However, data on the comparative signatures of t-PrP across the spectrum of prion diseases, longitudinal changes during disease progression, and levels in pre-clinical cases are scarce. T-PrP was quantified in neurological diseases (ND, n = 147) and in prion diseases from different aetiologies including sporadic (sCJD, n = 193), iatrogenic (iCJD, n = 12) and genetic (n = 209) forms. T-PrP was also measured in serial lumbar punctures obtained from sCJD cases at different symptomatic disease stages, and in asymptomatic prion protein gene (PRNP) mutation carriers. Compared to ND, t-PrP concentrations were significantly decreased in sCJD, iCJD and in genetic prion diseases associated with the three most common mutations E200K, V210I (associated with genetic CJD) and D178N-129M (associated with fatal familial insomnia). In contrast, t-PrP concentrations in P102L mutants (associated with the Gerstmann-Sträussler-Scheinker syndrome) remained unaltered. In serial lumbar punctures obtained at different disease stages of sCJD patients, t-PrP concentrations inversely correlated with disease progression. Decreased mean t-PrP values were detected in asymptomatic D178-129M mutant carriers, but not in E200K and P102L carriers. The presence of low CSF t-PrP is common to all types of prion diseases regardless of their aetiology albeit with mutation-specific exceptions in a minority of genetic cases. In some genetic prion disease, decreased levels are already detected at pre-clinical stages and diminish in parallel with disease progression. Our data indicate that CSF t-PrP concentrations may have a role as a pre-clinical or early symptomatic diagnostic biomarker in prion diseases as well as in the evaluation of therapeutic interventions.

KW - Cerebrospinal fluid

KW - Genetic prion disease

KW - Iatrogenic prion disease

KW - Prion protein

KW - Sporadic Creutzfeldt-Jakob disease

UR - http://www.scopus.com/inward/record.url?scp=85051101864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051101864&partnerID=8YFLogxK

U2 - 10.1007/s12035-018-1251-1

DO - 10.1007/s12035-018-1251-1

M3 - Article

JO - Molecular Neurobiology

JF - Molecular Neurobiology

SN - 0893-7648

ER -